$13.49
+0.79 (+6.22%)
Open$13.31
Previous Close$12.70
Day High$13.50
Day Low$12.85
52W High$39.75
52W Low$6.27
Volume—
Avg Volume37.6K
Market Cap32.57M
P/E Ratio—
EPS$-18.46
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+70.5% upside
Current
$13.49
$13.49
Target
$23.00
$23.00
$15.62
$23.00 avg
$28.09
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.59M | 3.48M | 3.01M |
| Net Income | 732.2K | 573.7K | 520.4K |
| Profit Margin | 20.4% | 16.5% | 17.3% |
| EBITDA | 1.09M | 1.00M | 849.7K |
| Free Cash Flow | 537.7K | 589.4K | 453.2K |
| Rev Growth | +3.4% | -1.6% | +9.6% |
| Debt/Equity | 0.28 | 0.26 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |